title: Disruption of the blood-brain barrier in Parkinson's disease: curse or route to a cure?
abstract: The vertebrate blood-brain barrier (BBB) is critical for ensuring the maintenance of brain homeostasis, whilst protecting the brain against toxic insults. Various pathological events disrupt BBB integrity, holding several important clinical implications. In instances where the normal mechanisms controlling passage of substances into the brain are compromised, these could sensitize or even worsen endogenous pathological conditions. Recognition has grown recently that patients diagnosed with Parkinson's disease (PD) present with concurrent medical problems, including cerebrovascular lesions. However, cerebrovascular disturbances may also result from PD-related disease processes; the pathological mechanisms which could entail interaction between environment-derived and genetic factors. The current review addresses the accumulation of studies aimed at better understanding the series of processes affecting the neurovascular unit in human Parkinsonism, due in part to the BBB presenting as a formidable opponent in the effective delivery of therapeutics that have shown promise as therapeutic strategies for treating aspects of PD when tested in vitro.
authors.affiliation: Centre for Neuroinflammation and Neurodegeneration, Division of Brain Sciences, Department of Medicine, Imperial College London, London, W12 ONN, United Kingdom.
authors.forename: Heyne
authors.initials: H
authors.lastname: Lee
authors.affiliation: Centre for Neuroinflammation and Neurodegeneration, Division of Brain Sciences, Department of Medicine, Imperial College London, London, W12 ONN, United Kingdom.
authors.forename: Ilse S
authors.initials: IS
authors.lastname: Pienaar
mesh_terms: D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001812:Blood-Brain Barrier; D016503:Drug Delivery Systems; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*
chemical_list: D000978:Antiparkinson Agents